Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Receivables (2024 - 2025)

PharmaCyte Biotech (PMCB) has disclosed Receivables for 5 consecutive years, with $3.4 million as the latest value for Q1 2025.

  • On a quarterly basis, Receivables changed N/A to $3.4 million in Q1 2025 year-over-year; TTM through Jan 2025 was $3.4 million, a N/A change, with the full-year FY2024 number at $2.8 million, changed N/A from a year prior.
  • Receivables was $3.4 million for Q1 2025 at PharmaCyte Biotech, up from $2.8 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $3.4 million in Q1 2025 to a low of $2.8 million in Q2 2024.